Georgios Hajishengallis

Title: Georgios Hajishengallis: Innovator in Mucosal Immunology

Introduction

Georgios Hajishengallis is a prominent inventor based in Birmingham, AL (US). He is known for his significant contributions to the field of mucosal immunology, particularly in the development of novel vaccines. His innovative work has the potential to enhance immune responses through oral immunization.

Latest Patents

Hajishengallis holds a patent for "Mucosal immunogens for novel vaccines." This invention provides chimeric proteins, such as Salivary Binding Protein (SBR) coupled to the B subunit of cholera toxin. The chimeric protein, when expressed in attenuated Salmonella typhimurium, produces significant increases in serum IgG and salivary IgA antibody levels after oral immunization. In another embodiment, the recombinant plasmid contains a salivary binding protein-cholera toxin A2/B chimeric protein expressed in E. coli. Intragastric immunization of SBR coupled to CTB in this chimeric protein form leads to increased antigen-responsive T cells. Additionally, the recombinant plasmid can contain a salivary binding protein-cholera toxin ΔA1 chimeric protein expressed in Salmonella typhimurium, resulting in increased serum IgG and salivary IgA responses to antigen.

Career Highlights

Hajishengallis is affiliated with the UAB Research Foundation, where he continues to advance his research in immunology. His work has garnered attention for its innovative approach to vaccine development, focusing on enhancing mucosal immunity.

Collaborations

Some of his notable coworkers include Michael W Russell and Susan K Hollingshead. Their collaborative efforts contribute to the ongoing research and development in the field of immunology.

Conclusion

Georgios Hajishengallis is a key figure in the advancement of mucosal immunology, with a focus on developing innovative vaccines. His patented work demonstrates the potential for significant improvements in immune responses through oral immunization.